VK4-116
highly selective dopamine D3 receptor (D3R) antagonist
Also Known As:
(R)-N-(4-(4-(3-chloro-5-ethyl-2-methoxyphenyl)piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide; R-VK4-116
Networked: 4
relevant articles (1 outcomes,
1 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
| 1. | Newman, Amy Hauck:
3 articles
(05/2022 - 01/2019)
|
| 2. | Xi, Zheng-Xiong:
3 articles
(05/2022 - 01/2019)
|
| 3. | Heidbreder, Christian:
1 article
(05/2022)
|
| 4. | Baumann, Michael H:
1 article
(12/2019)
|
| 5. | Humburg, Bree A:
1 article
(12/2019)
|
| 6. | Jordan, Chloe J:
1 article
(12/2019)
|
| 7. | Schindler, Charles W:
1 article
(12/2019)
|
| 8. | Shaik, Anver Basha:
1 article
(12/2019)
|
| 9. | Thorndike, Eric B:
1 article
(12/2019)
|
| 10. | Bi, Guo-Hua:
1 article
(01/2019)
|
Related Diseases
| 1. | Opioid-Related Disorders (Opiate Addiction)
01/01/2019
- " Taken together, these findings indicate a central role for D3Rs in opioid reward and support further development of VK4-116 as an effective agent for mitigating the development of opioid addiction, reducing the severity of withdrawal and preventing relapse." 01/01/2019
- " In this study, we evaluated-in laboratory rats-the potential utility of VK4-116, a novel and highly selective dopamine D3 receptor (D3R) antagonist, for the prevention and treatment of prescription opioid use disorders. " 12/01/2019
- " Recently, we developed two structurally novel D3R antagonists, R-VK4-40 and R-VK4-116, which are highly selective for D3R and display translational potential for treatment of opioid use disorder. " 01/01/2023
- " Finally, the discovery that highly selective D3R antagonists, such as R-VK4-116 and R-VK4-40, do not adversely affect peripheral biometrics or cardiovascular effects alone or in the presence of oxycodone or cocaine suggests that this class of drugs has great potential in safely treating psychostimulant and/or opioid use disorders."
|
| 2. | Hyperalgesia
|
|
Related Drugs and Biologics
Related Therapies and Procedures